The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...

The expression of MICA/B cell-surface proteins is induced by cellular stress or malignant transformation, and is detectable ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Discover five T cell engager companies that have emerged in recent times, as this class of therapeutics is set to take off.

so the CAR T-cell therapies eliminate some healthy cells. However, patients can survive without B cells. With solid tumors, ...

When thinking about the immune system, most people think about B and T cells and how they can be trained to recognize ...

The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Cell Therapy Discovery & ...

Radiation injury poses a serious threat to human health, causing complex and multifaceted damage to cells and tissues. Such ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

Research from the Wellcome Sanger Institute reveals that younger stem cell donors lead to better transplant outcomes.